BioRestorative Therapies, Inc. (BRTX) 10-Year Financial Performance & Capital Metrics

BRTX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutBioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.Show more

Revenue $401K +175.0%
EBITDA -$11M +24.5%
Net Income -$9M +13.8%
EPS (Diluted) -1.16 +53.0%
Gross Margin 93% -7.0%
EBITDA Margin -2834.45% +72.5%
Operating Margin -2881.59% +72.4%
Net Margin -2239.25% +68.7%
ROE -96.89% +5.6%
ROIC -100.39% +20.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 25.3%
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 84.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.37%

5Y25.27%

3Y105.81%

TTM1.7%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-105.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM-108.45%

ROCE

10Y Avg-136.13%

5Y Avg-136.13%

3Y Avg-130.03%

Latest-124.68%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	628.91K	36.35K	81K	111K	130K	77K	46K	119.8K	145.8K	401K
Revenue Growth %	0.51%	-0.94%	1.23%	0.37%	0.17%	-0.41%	-0.4%	1.6%	0.22%	1.75%
Cost of Goods Sold+	261.5K	102	259.26K	0	0	0	0	0	0	28.07K
COGS % of Revenue	0.42%	0%	3.2%	-	-	-	-	-	-	0.07%
Gross Profit+	367.41K	36.25K	-178.26K	111K	130K	77K	46K	119.8K	145.8K	372.93K
Gross Margin %	0.58%	1%	-2.2%	1%	1%	1%	1%	1%	1%	0.93%
Gross Profit Growth %	0.82%	-0.9%	-5.92%	1.62%	0.17%	-0.41%	-0.4%	1.6%	0.22%	1.56%
Operating Expenses+	7.54M	7.83M	8.46M	7.76M	8.56M	2.83M	26.35M	19.09M	15.37M	11.93M
OpEx % of Revenue	11.99%	215.47%	104.39%	69.9%	65.86%	36.74%	572.91%	159.38%	105.39%	29.75%
Selling, General & Admin	5.43M	4.95M	6.3M	6.25M	6.84M	1.95M	25.62M	15.58M	11.33M	6.58M
SG&A % of Revenue	8.64%	136.16%	77.81%	56.27%	52.61%	25.35%	557.06%	130.05%	77.72%	16.41%
Research & Development	2.11M	2.88M	2.15M	1.51M	1.72M	876.83K	729.06K	3.51M	4.03M	5.35M
R&D % of Revenue	3.35%	79.32%	26.57%	13.63%	13.25%	11.39%	15.85%	29.33%	27.67%	13.34%
Other Operating Expenses	0	-46.6K	-59.94K	0	0	0	0	0	0	0
Operating Income+	-7.17M	-7.8M	-8.37M	-7.65M	-8.43M	-2.75M	-26.31M	-18.97M	-15.22M	-11.56M
Operating Margin %	-11.4%	-214.48%	-103.39%	-68.9%	-64.86%	-35.74%	-571.91%	-158.38%	-104.39%	-28.82%
Operating Income Growth %	-0.46%	-0.09%	-0.07%	0.09%	-0.1%	0.67%	-8.56%	0.28%	0.2%	0.24%
EBITDA+	-6.96M	-7.54M	-8.12M	-7.41M	-8.21M	-2.6M	-26.22M	-18.85M	-15.06M	-11.37M
EBITDA Margin %	-11.06%	-207.37%	-100.19%	-66.73%	-63.19%	-33.77%	-569.97%	-157.37%	-103.26%	-28.34%
EBITDA Growth %	-0.44%	-0.08%	-0.08%	0.09%	-0.11%	0.68%	-9.08%	0.28%	0.2%	0.25%
D&A (Non-Cash Add-back)	213.78K	258.43K	259.26K	240.37K	217.45K	151.96K	89.11K	120.55K	165.74K	189.06K
EBIT	-7.32M	-7.87M	-8.36M	-9.3M	-9.51M	-9.63M	-26.31M	-18.86M	-15.14M	-11.56M
Net Interest Income+	-603.03K	-763.94K	-1.09M	-3.22M	-5.14M	-1.64M	-1.82M	11.65K	552.29K	616.08K
Interest Income	0	0	0	0	0	0	0	11.65K	552.29K	616.08K
Interest Expense	603.03K	763.94K	1.09M	3.22M	5.14M	1.64M	1.82M	0	0	0
Other Income/Expense	-753.12K	-839.03K	-1.07M	-4.87M	-6.22M	-8.52M	-18M	5.75M	4.8M	2.58M
Pretax Income+	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Pretax Margin %	-12.6%	-237.55%	-116.6%	-112.77%	-112.68%	-146.4%	-963.12%	-110.37%	-71.45%	-22.39%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Net Margin %	-12.6%	-237.55%	-116.6%	-112.77%	-112.68%	-146.4%	-963.12%	-110.37%	-71.45%	-22.39%
Net Income Growth %	-0.42%	-0.09%	-0.09%	-0.33%	-0.17%	0.23%	-2.93%	0.7%	0.21%	0.14%
Net Income (Continuing)	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9580.99	-7356.30	-6181.06	-4269.37	-3217.82	-28.56	-37.30	-3.65	-2.47	-1.16
EPS Growth %	0.27%	0.23%	0.16%	0.31%	0.25%	0.99%	-0.31%	0.9%	0.32%	0.53%
EPS (Basic)	-9580.99	-7356.30	-6181.06	-4269.37	-3217.82	-28.56	-37.30	-3.65	-2.47	-1.16
Diluted Shares Outstanding	827	1.17K	1.53K	2.93K	5.57K	394.7K	1.19M	3.62M	4.22M	7.76M
Basic Shares Outstanding	827	1.17K	1.53K	2.93K	5.57K	394.7K	1.19M	3.62M	4.22M	7.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	289.28K	61.68K	519.71K	180.99K	68.86K	3.19M	21.47M	15.13M	11.39M	11.14M
Cash & Short-Term Investments	166.56K	31.82K	451.68K	117.52K	1.66K	3.06M	21.03M	14.75M	11.07M	10.73M
Cash Only	166.56K	31.82K	451.68K	117.52K	1.66K	3.06M	21.03M	1.71M	884.38K	547.89K
Short-Term Investments	0	0	0	0	0	0	0	13.04M	10.18M	10.18M
Accounts Receivable	93.38K	6K	38K	29K	32K	17K	5K	16K	19.3K	188.4K
Days Sales Outstanding	54.19	60.24	171.23	95.36	89.85	80.58	39.67	48.75	48.32	171.49
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	29.35K	0	30.03K	34.46K	0	0	0	0	0	223.23K
Total Non-Current Assets+	1.73M	1.52M	1.24M	1.01M	1.4M	1.16M	985.54K	1.31M	1.22M	1.14M
Property, Plant & Equipment	643.09K	508.59K	327.85K	175.24K	658.3K	495.76K	395.8K	502.76K	507.5K	362.94K
Fixed Asset Turnover	0.98x	0.07x	0.25x	0.63x	0.20x	0.16x	0.12x	0.24x	0.29x	1.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.04M	963.85K	888.95K	814.06K	739.16K	664.27K	589.74K	803.44K	713.69K	623.95K
Long-Term Investments	0	45.9K	22.1K	0	0	0	0	0	0	0
Other Non-Current Assets	45.9K	45.9K	22.1K	22.1K	0	0	0	1	0	148.7K
Total Assets+	2.02M	1.58M	1.76M	1.19M	1.47M	4.35M	22.45M	16.43M	12.61M	12.28M
Asset Turnover	0.31x	0.02x	0.05x	0.09x	0.09x	0.02x	0.00x	0.01x	0.01x	0.03x
Asset Growth %	0.19%	-0.22%	0.11%	-0.32%	0.23%	1.96%	4.17%	-0.27%	-0.23%	-0.03%
Total Current Liabilities+	5.61M	5.84M	8.35M	9.25M	13.72M	1.04M	363.82K	5.98M	2.61M	3.75M
Accounts Payable	2.55M	2.28M	2.45M	1.89M	1.95M	118.85K	50.83K	170.9K	189.39K	483.07K
Days Payables Outstanding	3.56K	1000K	3.46K	-	-	-	-	-	-	6.28K
Short-Term Debt	1.01M	1.86M	3.47M	3.63M	7.23M	0	58.97K	0	162.32K	0
Deferred Revenue (Current)	43.6K	0	1000K	1000K	1000K	0	0	0	0	0
Other Current Liabilities	1.04M	821.74K	216.07K	1.09M	-2.22M	657.6K	106.6K	5.54M	2.26M	2.52M
Current Ratio	0.05x	0.01x	0.06x	0.02x	0.01x	3.05x	59.01x	2.53x	4.37x	2.97x
Quick Ratio	0.05x	0.01x	0.06x	0.02x	0.01x	3.05x	59.01x	2.53x	4.37x	2.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	313.01K	735.44K	241.87K	578.53K	521.89K	4.63M	492.68K	162.32K	0	0
Long-Term Debt	302K	297.76K	194.28K	523.89K	0	4.27M	191.03K	0	0	0
Capital Lease Obligations	0	0	0	0	521.89K	363.52K	301.64K	162.32K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.01K	437.68K	47.59K	54.64K	0	0	0	0	0	0
Total Liabilities	5.93M	6.58M	8.6M	9.83M	14.24M	5.68M	856.5K	6.14M	2.61M	3.75M
Total Debt+	1.31M	2.16M	3.66M	4.15M	7.84M	4.79M	670.7K	301.64K	162.32K	0
Net Debt	1.15M	2.12M	3.21M	4.03M	7.84M	1.73M	-20.36M	-1.41M	-722.06K	-547.89K
Debt / Equity	-	-	-	-	-	-	0.03x	0.03x	0.02x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.89x	-10.21x	-7.70x	-2.37x	-1.64x	-1.68x	-14.49x	-	-	-
Total Equity+	-3.91M	-5M	-6.84M	-8.64M	-12.78M	-1.33M	21.6M	10.29M	10M	8.53M
Equity Growth %	0.43%	-0.28%	-0.37%	-0.26%	-0.48%	0.9%	17.22%	-0.52%	-0.03%	-0.15%
Book Value per Share	-4726.07	-4259.18	-4474.19	-2947.15	-2294.15	-3.37	18.18	2.84	2.37	1.10
Total Shareholders' Equity	-3.91M	-5M	-6.84M	-8.64M	-12.78M	-1.33M	21.6M	10.29M	10M	8.53M
Common Stock	3.34K	4.7K	6.11K	11.73K	7.79K	72	353	369	471	692
Retained Earnings	-33.32M	-41.96M	-51.4M	-63.92M	-78.57M	-89.84M	-134.15M	-136.28M	-146.7M	-155.68M
Treasury Stock	-32K	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.12M	-5M	-3.85M	-5.1M	-6.92M	-1.96M	-3.33M	-5.91M	-6.43M	-8.23M
Operating CF Margin %	-4.96%	-137.61%	-47.58%	-45.99%	-53.22%	-25.51%	-72.39%	-49.36%	-44.1%	-20.52%
Operating CF Growth %	0.03%	-0.6%	0.23%	-0.32%	-0.36%	0.72%	-0.7%	-0.78%	-0.09%	-0.28%
Net Income	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Depreciation & Amortization	213.78K	258.43K	259.26K	240.37K	217.36K	121.38K	89.11K	120.55K	165.74K	189.06K
Stock-Based Compensation	1.95M	2.54M	3.6M	2.4M	1.66M	691.7K	23.11M	12.61M	7.78M	2.81M
Deferred Taxes	460.21K	87.27K	-17K	1.65M	1.11M	0	0	0	0	0
Other Non-Cash Items	114.42K	570.21K	926.45K	3.17M	4.21M	7.92M	17.45M	-5.44M	-4.48M	-2.28M
Working Capital Changes	2.06M	180.93K	821.33K	-45.78K	539.85K	572.35K	324.69K	14.14K	515.33K	28.65K
Change in Receivables	-93.38K	87.38K	-32K	9K	-3K	15K	12K	-11K	-3.3K	-169.1K
Change in Inventory	934.59K	5.99M	655.29K	9.54M	423.65K	0	0	0	0	0
Change in Payables	1.38M	-113.15K	185.96K	-516.12K	97.1K	84.63K	-68.02K	120.08K	18.49K	293.68K
Cash from Investing+	-483.07K	-188.76K	-3.62K	-12.87K	-35.63K	0	-30.66K	-13.4M	3.25M	514.53K
Capital Expenditures	-483.07K	-188.76K	-3.62K	-12.87K	-35.63K	0	-30.66K	-265.22K	-171.04K	-106.19K
CapEx % of Revenue	0.77%	5.19%	0.04%	0.12%	0.27%	-	0.67%	2.21%	1.17%	0.26%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-75K	0	0	0	0	0	0	-175K	0	0
Cash from Financing+	3.68M	5.06M	4.28M	4.78M	6.84M	5.03M	21.32M	0	2.35M	7.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	441.17K	140.87K	981.25K	414.17K	0	-500K	0	0	0	7.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.61M	-5.19M	-3.86M	-5.12M	-6.95M	-1.96M	-3.36M	-6.35M	-6.6M	-8.34M
FCF Margin %	-5.73%	-142.8%	-47.62%	-46.1%	-53.5%	-25.51%	-73.06%	-53.03%	-45.28%	-20.79%
FCF Growth %	-0.06%	-0.44%	0.26%	-0.33%	-0.36%	0.72%	-0.71%	-0.89%	-0.04%	-0.26%
FCF per Share	-4359.29	-4422.01	-2524.50	-1745.39	-1248.76	-4.98	-2.83	-1.76	-1.56	-1.07
FCF Conversion (FCF/Net Income)	0.39x	0.58x	0.41x	0.41x	0.47x	0.17x	0.08x	0.45x	0.62x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-437.23%	-82.93%	-102.66%	-96.89%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-2410.7%	-281.26%	-125.72%	-100.39%
Gross Margin	58.42%	99.72%	-220.07%	100%	100%	100%	100%	100%	100%	93%
Net Margin	-1259.87%	-23755.44%	-11660.07%	-11277.3%	-11267.61%	-14639.85%	-96311.51%	-11036.98%	-7145.2%	-2239.25%
Debt / Equity	-	-	-	-	-	-	0.03x	0.03x	0.02x	-
Interest Coverage	-11.89x	-10.21x	-7.70x	-2.37x	-1.64x	-1.68x	-14.49x	-	-	-
FCF Conversion	0.39x	0.58x	0.41x	0.41x	0.47x	0.17x	0.08x	0.45x	0.62x	0.92x
Revenue Growth	51.18%	-94.22%	122.8%	37.04%	17.12%	-40.77%	-40.26%	160.43%	21.7%	175.03%

Revenue by Segment

	2013	2014	2015	2024
Product	-	-	-	300K
Product Growth	-	-	-	-
Royalty	-	-	-	101K
Royalty Growth	-	-	-	-
Stem Pearls Skincare Products	1.68K	2.22K	425	-
Stem Pearls Skincare Products Growth	-	32.08%	-80.85%	-

Frequently Asked Questions

Growth & Financials

BioRestorative Therapies, Inc. (BRTX) reported $0.4M in revenue for fiscal year 2024.

BioRestorative Therapies, Inc. (BRTX) grew revenue by 175.0% over the past year. This is strong growth.

BioRestorative Therapies, Inc. (BRTX) reported a net loss of $12.7M for fiscal year 2024.

Dividend & Returns

BioRestorative Therapies, Inc. (BRTX) has a return on equity (ROE) of -96.9%. Negative ROE indicates the company is unprofitable.

BioRestorative Therapies, Inc. (BRTX) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioRestorative Therapies, Inc. (BRTX) 10-Year Financial Performance & Capital Metrics

BRTX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $401K +175.0%
EBITDA -$11M +24.5%
Net Income -$9M +13.8%
EPS (Diluted) -1.16 +53.0%
Gross Margin 93% -7.0%
EBITDA Margin -2834.45% +72.5%
Operating Margin -2881.59% +72.4%
Net Margin -2239.25% +68.7%
ROE -96.89% +5.6%
ROIC -100.39% +20.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 25.3%
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 84.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.37%

5Y25.27%

3Y105.81%

TTM1.7%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-105.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM-108.45%

ROCE

10Y Avg-136.13%

5Y Avg-136.13%

3Y Avg-130.03%

Latest-124.68%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	628.91K	36.35K	81K	111K	130K	77K	46K	119.8K	145.8K	401K
Revenue Growth %	0.51%	-0.94%	1.23%	0.37%	0.17%	-0.41%	-0.4%	1.6%	0.22%	1.75%
Cost of Goods Sold+	261.5K	102	259.26K	0	0	0	0	0	0	28.07K
COGS % of Revenue	0.42%	0%	3.2%	-	-	-	-	-	-	0.07%
Gross Profit+	367.41K	36.25K	-178.26K	111K	130K	77K	46K	119.8K	145.8K	372.93K
Gross Margin %	0.58%	1%	-2.2%	1%	1%	1%	1%	1%	1%	0.93%
Gross Profit Growth %	0.82%	-0.9%	-5.92%	1.62%	0.17%	-0.41%	-0.4%	1.6%	0.22%	1.56%
Operating Expenses+	7.54M	7.83M	8.46M	7.76M	8.56M	2.83M	26.35M	19.09M	15.37M	11.93M
OpEx % of Revenue	11.99%	215.47%	104.39%	69.9%	65.86%	36.74%	572.91%	159.38%	105.39%	29.75%
Selling, General & Admin	5.43M	4.95M	6.3M	6.25M	6.84M	1.95M	25.62M	15.58M	11.33M	6.58M
SG&A % of Revenue	8.64%	136.16%	77.81%	56.27%	52.61%	25.35%	557.06%	130.05%	77.72%	16.41%
Research & Development	2.11M	2.88M	2.15M	1.51M	1.72M	876.83K	729.06K	3.51M	4.03M	5.35M
R&D % of Revenue	3.35%	79.32%	26.57%	13.63%	13.25%	11.39%	15.85%	29.33%	27.67%	13.34%
Other Operating Expenses	0	-46.6K	-59.94K	0	0	0	0	0	0	0
Operating Income+	-7.17M	-7.8M	-8.37M	-7.65M	-8.43M	-2.75M	-26.31M	-18.97M	-15.22M	-11.56M
Operating Margin %	-11.4%	-214.48%	-103.39%	-68.9%	-64.86%	-35.74%	-571.91%	-158.38%	-104.39%	-28.82%
Operating Income Growth %	-0.46%	-0.09%	-0.07%	0.09%	-0.1%	0.67%	-8.56%	0.28%	0.2%	0.24%
EBITDA+	-6.96M	-7.54M	-8.12M	-7.41M	-8.21M	-2.6M	-26.22M	-18.85M	-15.06M	-11.37M
EBITDA Margin %	-11.06%	-207.37%	-100.19%	-66.73%	-63.19%	-33.77%	-569.97%	-157.37%	-103.26%	-28.34%
EBITDA Growth %	-0.44%	-0.08%	-0.08%	0.09%	-0.11%	0.68%	-9.08%	0.28%	0.2%	0.25%
D&A (Non-Cash Add-back)	213.78K	258.43K	259.26K	240.37K	217.45K	151.96K	89.11K	120.55K	165.74K	189.06K
EBIT	-7.32M	-7.87M	-8.36M	-9.3M	-9.51M	-9.63M	-26.31M	-18.86M	-15.14M	-11.56M
Net Interest Income+	-603.03K	-763.94K	-1.09M	-3.22M	-5.14M	-1.64M	-1.82M	11.65K	552.29K	616.08K
Interest Income	0	0	0	0	0	0	0	11.65K	552.29K	616.08K
Interest Expense	603.03K	763.94K	1.09M	3.22M	5.14M	1.64M	1.82M	0	0	0
Other Income/Expense	-753.12K	-839.03K	-1.07M	-4.87M	-6.22M	-8.52M	-18M	5.75M	4.8M	2.58M
Pretax Income+	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Pretax Margin %	-12.6%	-237.55%	-116.6%	-112.77%	-112.68%	-146.4%	-963.12%	-110.37%	-71.45%	-22.39%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Net Margin %	-12.6%	-237.55%	-116.6%	-112.77%	-112.68%	-146.4%	-963.12%	-110.37%	-71.45%	-22.39%
Net Income Growth %	-0.42%	-0.09%	-0.09%	-0.33%	-0.17%	0.23%	-2.93%	0.7%	0.21%	0.14%
Net Income (Continuing)	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9580.99	-7356.30	-6181.06	-4269.37	-3217.82	-28.56	-37.30	-3.65	-2.47	-1.16
EPS Growth %	0.27%	0.23%	0.16%	0.31%	0.25%	0.99%	-0.31%	0.9%	0.32%	0.53%
EPS (Basic)	-9580.99	-7356.30	-6181.06	-4269.37	-3217.82	-28.56	-37.30	-3.65	-2.47	-1.16
Diluted Shares Outstanding	827	1.17K	1.53K	2.93K	5.57K	394.7K	1.19M	3.62M	4.22M	7.76M
Basic Shares Outstanding	827	1.17K	1.53K	2.93K	5.57K	394.7K	1.19M	3.62M	4.22M	7.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	289.28K	61.68K	519.71K	180.99K	68.86K	3.19M	21.47M	15.13M	11.39M	11.14M
Cash & Short-Term Investments	166.56K	31.82K	451.68K	117.52K	1.66K	3.06M	21.03M	14.75M	11.07M	10.73M
Cash Only	166.56K	31.82K	451.68K	117.52K	1.66K	3.06M	21.03M	1.71M	884.38K	547.89K
Short-Term Investments	0	0	0	0	0	0	0	13.04M	10.18M	10.18M
Accounts Receivable	93.38K	6K	38K	29K	32K	17K	5K	16K	19.3K	188.4K
Days Sales Outstanding	54.19	60.24	171.23	95.36	89.85	80.58	39.67	48.75	48.32	171.49
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	29.35K	0	30.03K	34.46K	0	0	0	0	0	223.23K
Total Non-Current Assets+	1.73M	1.52M	1.24M	1.01M	1.4M	1.16M	985.54K	1.31M	1.22M	1.14M
Property, Plant & Equipment	643.09K	508.59K	327.85K	175.24K	658.3K	495.76K	395.8K	502.76K	507.5K	362.94K
Fixed Asset Turnover	0.98x	0.07x	0.25x	0.63x	0.20x	0.16x	0.12x	0.24x	0.29x	1.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.04M	963.85K	888.95K	814.06K	739.16K	664.27K	589.74K	803.44K	713.69K	623.95K
Long-Term Investments	0	45.9K	22.1K	0	0	0	0	0	0	0
Other Non-Current Assets	45.9K	45.9K	22.1K	22.1K	0	0	0	1	0	148.7K
Total Assets+	2.02M	1.58M	1.76M	1.19M	1.47M	4.35M	22.45M	16.43M	12.61M	12.28M
Asset Turnover	0.31x	0.02x	0.05x	0.09x	0.09x	0.02x	0.00x	0.01x	0.01x	0.03x
Asset Growth %	0.19%	-0.22%	0.11%	-0.32%	0.23%	1.96%	4.17%	-0.27%	-0.23%	-0.03%
Total Current Liabilities+	5.61M	5.84M	8.35M	9.25M	13.72M	1.04M	363.82K	5.98M	2.61M	3.75M
Accounts Payable	2.55M	2.28M	2.45M	1.89M	1.95M	118.85K	50.83K	170.9K	189.39K	483.07K
Days Payables Outstanding	3.56K	1000K	3.46K	-	-	-	-	-	-	6.28K
Short-Term Debt	1.01M	1.86M	3.47M	3.63M	7.23M	0	58.97K	0	162.32K	0
Deferred Revenue (Current)	43.6K	0	1000K	1000K	1000K	0	0	0	0	0
Other Current Liabilities	1.04M	821.74K	216.07K	1.09M	-2.22M	657.6K	106.6K	5.54M	2.26M	2.52M
Current Ratio	0.05x	0.01x	0.06x	0.02x	0.01x	3.05x	59.01x	2.53x	4.37x	2.97x
Quick Ratio	0.05x	0.01x	0.06x	0.02x	0.01x	3.05x	59.01x	2.53x	4.37x	2.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	313.01K	735.44K	241.87K	578.53K	521.89K	4.63M	492.68K	162.32K	0	0
Long-Term Debt	302K	297.76K	194.28K	523.89K	0	4.27M	191.03K	0	0	0
Capital Lease Obligations	0	0	0	0	521.89K	363.52K	301.64K	162.32K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.01K	437.68K	47.59K	54.64K	0	0	0	0	0	0
Total Liabilities	5.93M	6.58M	8.6M	9.83M	14.24M	5.68M	856.5K	6.14M	2.61M	3.75M
Total Debt+	1.31M	2.16M	3.66M	4.15M	7.84M	4.79M	670.7K	301.64K	162.32K	0
Net Debt	1.15M	2.12M	3.21M	4.03M	7.84M	1.73M	-20.36M	-1.41M	-722.06K	-547.89K
Debt / Equity	-	-	-	-	-	-	0.03x	0.03x	0.02x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-11.89x	-10.21x	-7.70x	-2.37x	-1.64x	-1.68x	-14.49x	-	-	-
Total Equity+	-3.91M	-5M	-6.84M	-8.64M	-12.78M	-1.33M	21.6M	10.29M	10M	8.53M
Equity Growth %	0.43%	-0.28%	-0.37%	-0.26%	-0.48%	0.9%	17.22%	-0.52%	-0.03%	-0.15%
Book Value per Share	-4726.07	-4259.18	-4474.19	-2947.15	-2294.15	-3.37	18.18	2.84	2.37	1.10
Total Shareholders' Equity	-3.91M	-5M	-6.84M	-8.64M	-12.78M	-1.33M	21.6M	10.29M	10M	8.53M
Common Stock	3.34K	4.7K	6.11K	11.73K	7.79K	72	353	369	471	692
Retained Earnings	-33.32M	-41.96M	-51.4M	-63.92M	-78.57M	-89.84M	-134.15M	-136.28M	-146.7M	-155.68M
Treasury Stock	-32K	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.12M	-5M	-3.85M	-5.1M	-6.92M	-1.96M	-3.33M	-5.91M	-6.43M	-8.23M
Operating CF Margin %	-4.96%	-137.61%	-47.58%	-45.99%	-53.22%	-25.51%	-72.39%	-49.36%	-44.1%	-20.52%
Operating CF Growth %	0.03%	-0.6%	0.23%	-0.32%	-0.36%	0.72%	-0.7%	-0.78%	-0.09%	-0.28%
Net Income	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.3M	-13.22M	-10.42M	-8.98M
Depreciation & Amortization	213.78K	258.43K	259.26K	240.37K	217.36K	121.38K	89.11K	120.55K	165.74K	189.06K
Stock-Based Compensation	1.95M	2.54M	3.6M	2.4M	1.66M	691.7K	23.11M	12.61M	7.78M	2.81M
Deferred Taxes	460.21K	87.27K	-17K	1.65M	1.11M	0	0	0	0	0
Other Non-Cash Items	114.42K	570.21K	926.45K	3.17M	4.21M	7.92M	17.45M	-5.44M	-4.48M	-2.28M
Working Capital Changes	2.06M	180.93K	821.33K	-45.78K	539.85K	572.35K	324.69K	14.14K	515.33K	28.65K
Change in Receivables	-93.38K	87.38K	-32K	9K	-3K	15K	12K	-11K	-3.3K	-169.1K
Change in Inventory	934.59K	5.99M	655.29K	9.54M	423.65K	0	0	0	0	0
Change in Payables	1.38M	-113.15K	185.96K	-516.12K	97.1K	84.63K	-68.02K	120.08K	18.49K	293.68K
Cash from Investing+	-483.07K	-188.76K	-3.62K	-12.87K	-35.63K	0	-30.66K	-13.4M	3.25M	514.53K
Capital Expenditures	-483.07K	-188.76K	-3.62K	-12.87K	-35.63K	0	-30.66K	-265.22K	-171.04K	-106.19K
CapEx % of Revenue	0.77%	5.19%	0.04%	0.12%	0.27%	-	0.67%	2.21%	1.17%	0.26%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-75K	0	0	0	0	0	0	-175K	0	0
Cash from Financing+	3.68M	5.06M	4.28M	4.78M	6.84M	5.03M	21.32M	0	2.35M	7.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	441.17K	140.87K	981.25K	414.17K	0	-500K	0	0	0	7.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.61M	-5.19M	-3.86M	-5.12M	-6.95M	-1.96M	-3.36M	-6.35M	-6.6M	-8.34M
FCF Margin %	-5.73%	-142.8%	-47.62%	-46.1%	-53.5%	-25.51%	-73.06%	-53.03%	-45.28%	-20.79%
FCF Growth %	-0.06%	-0.44%	0.26%	-0.33%	-0.36%	0.72%	-0.71%	-0.89%	-0.04%	-0.26%
FCF per Share	-4359.29	-4422.01	-2524.50	-1745.39	-1248.76	-4.98	-2.83	-1.76	-1.56	-1.07
FCF Conversion (FCF/Net Income)	0.39x	0.58x	0.41x	0.41x	0.47x	0.17x	0.08x	0.45x	0.62x	0.92x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-437.23%	-82.93%	-102.66%	-96.89%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-2410.7%	-281.26%	-125.72%	-100.39%
Gross Margin	58.42%	99.72%	-220.07%	100%	100%	100%	100%	100%	100%	93%
Net Margin	-1259.87%	-23755.44%	-11660.07%	-11277.3%	-11267.61%	-14639.85%	-96311.51%	-11036.98%	-7145.2%	-2239.25%
Debt / Equity	-	-	-	-	-	-	0.03x	0.03x	0.02x	-
Interest Coverage	-11.89x	-10.21x	-7.70x	-2.37x	-1.64x	-1.68x	-14.49x	-	-	-
FCF Conversion	0.39x	0.58x	0.41x	0.41x	0.47x	0.17x	0.08x	0.45x	0.62x	0.92x
Revenue Growth	51.18%	-94.22%	122.8%	37.04%	17.12%	-40.77%	-40.26%	160.43%	21.7%	175.03%

Revenue by Segment

	2013	2014	2015	2024
Product	-	-	-	300K
Product Growth	-	-	-	-
Royalty	-	-	-	101K
Royalty Growth	-	-	-	-
Stem Pearls Skincare Products	1.68K	2.22K	425	-
Stem Pearls Skincare Products Growth	-	32.08%	-80.85%	-

Frequently Asked Questions

Growth & Financials

BioRestorative Therapies, Inc. (BRTX) reported $0.4M in revenue for fiscal year 2024.

BioRestorative Therapies, Inc. (BRTX) grew revenue by 175.0% over the past year. This is strong growth.

BioRestorative Therapies, Inc. (BRTX) reported a net loss of $12.7M for fiscal year 2024.

Dividend & Returns

BioRestorative Therapies, Inc. (BRTX) has a return on equity (ROE) of -96.9%. Negative ROE indicates the company is unprofitable.

BioRestorative Therapies, Inc. (BRTX) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.